title: [Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis].
abstract: OBJECTIVE
  To evaluate a new effective treatment for prostatodynia (PD) and chronic non-bacterial prostatitis (CNP).
  
  
  METHODS
  One hundred and thirty-six patients suffered from PD or CNP were divided randomly into experiment group (n = 76), which were treated with external RF hyperthermia (ERFH) combining with alpha 1-adrenergic receptor blocker Terazosin for 12 weeks, and control group (n = 60), which were only treated with ERFH. Symptoms scores, urodynamic indexes and expressed prostate secretion were recorded pre- and post-treatments.
  
  
  RESULTS
  MFR and AFR were significantly improved and symptoms scores significantly decreased in both groups (P < 0.05). The efficacy was better in experiment group than that in control group. The combination treatment also led to a significantly decrease in MUP and MUCP (P < 0.05). Additionally, the leucocytes in expressed prostate secretion were also reduced in experiment group (P < 0.05).
  
  
  CONCLUSIONS
  Treatment of ERFH combining with alpha 1-adrenergic receptor blocker for patients with PD or CNP was effective and had little side-effect, while the future curative effect should be observed furtherly.
authors.affiliation: Department of Urology, People's First Hospital of Yuxi, Yuxi, Yunnan 653100, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.forename: Rong
authors.initials: R
authors.lastname: Lu
authors.forename: Jun-Mei
authors.initials: JM
authors.lastname: Wang
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D059408:Pain Management; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy* / Q000628:therapy
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin